{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-034741","form_type":"8-K","ticker":"VKTX","cik":"0001607678","company_name":"Viking Therapeutics, Inc.","filed_at":"2023-07-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.539461+00:00","generated_at":"2026-06-13T02:21:26.751362+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Viking reports positive Phase 2b NASH data, $393M cash; net loss $19.2M","bullets":["VK2809 Phase 2b VOYAGE hit primary endpoint: median liver fat reduction 38-55%; up to 85% of patients achieved ≥30% reduction.","VK2809 showed significant reductions in LDL-C and triglycerides; Phase 2b 52-week biopsy results expected 1H24.","Phase 2 study of obesity candidate VK2735 to start 3Q23; Phase 1 oral formulation data expected 4Q23.","Net loss $19.2M ($0.19 loss/share) vs $17.4M ($0.23) in Q2 2022; R&D spend $13.9M, G&A $9.8M.","Ended Q2 with $393M cash, boosted by $288M stock offering; cash runway through multiple catalysts."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-034741","json":"https://secwatch.observer/filing/0000950170-23-034741.json","markdown":"https://secwatch.observer/filing/0000950170-23-034741.md","text":"https://secwatch.observer/filing/0000950170-23-034741.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1607678/000095017023034741/0000950170-23-034741-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1607678/000095017023034741/vktx-20230726.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T02:21:26.751362+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"38363e450aa33cfa20ff2f47806a70934ada5de1","claim":"Viking Therapeutics, Inc. reported financial results for second quarter and six months ended June 30, 2023.","evidence_excerpt":"On July 26, 2023, we issued a press release reporting our financial results for the second quarter and six months ended June 30, 2023 and providing a corporate update.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1607678/000095017023034741/0000950170-23-034741-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"second quarter and six months ended June 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}